- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Harvest Health & Recreation Issues Q4 and Year End 2018 Results
Harvest Health & Recreation announced its financial results for the Q4 and fiscal year 2018.
Harvest Health & Recreation (CSE:HARV,OTCQX:HRVSF) announced its financial results for the Q4 and fiscal year 2018.
As quoted in the press release:
“2018 continued to set records for Harvest’s growth and momentum across the United States,” said Chief Executive Officer Steve White. “Three key initiatives dictated our decisions throughout the year and will continue to be our focus in 2019: aggressively expanding our retail and wholesale footprint across the US, building, acquiring and expanding our suite of brands across our footprint and continuing to operate in a financially disciplined way, while also fueling the revenue growth of the company.”
Financial Highlights for the Fourth Quarter Ended December 31, 2018
- Total revenue was US$16.9 million, an increase of 135 [percent], compared to US$7.2 million in Q4 2017.
- Total revenue increased 52 [percent] compared to US$11.2 million in Q3 2018.
- Gross profit, excluding impact of biological assets, was US$7.2 million, an increase of 342 [percent], up from US$1.6 million in Q4 2017.
- Gross profit margin, excluding the impact of biological assets, was 42 [percent] and 23 [percent], respectively, for Q4 2018 and Q4 2017.
- Adjusted EBITDA was US$2.6 million, compared to US$2.2 million in Q4 2017.
- Net loss was US$71.1 million, for the three months ended December 31, 2018, and includes a non-recurring, non-cash fair value charge of US$50.7 million associated with convertible debt that was converted to equity during the year.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.